Assessment of the Efficacy of Cryolipolysis on Abdominal Fat Deposits: A Prospective Study

Aesthetic Plastic Surgery, Год журнала: 2023, Номер 47(6), С. 2679 - 2686

Опубликована: Май 3, 2023

Язык: Английский

---

Fractional Co2 laser for vulvo-vaginal atrophy in gynecologic cancer patients: A valid therapeutic choice? A systematic review

European Journal of Obstetrics & Gynecology and Reproductive Biology, Год журнала: 2022, Номер 277, С. 84 - 89

Опубликована: Авг. 23, 2022

Язык: Английский

---

Nanofat in Plastic Reconstructive, Regenerative, and Aesthetic Surgery: A Review of Advancements in Face-Focused Applications

Journal of Clinical Medicine, Год журнала: 2023, Номер 12(13), С. 4351 - 4351

Опубликована: Июнь 28, 2023

Nanofat is a relatively novel technique in fat grafting that has gained significant interest the fields of regenerative medicine, aesthetic and translational research. It involves extraction autologous from patient, which then transformed into “nanofat”, consisting small particles with diameter less than 0.1 mm containing high concentrations stem cells growth factors. This article focuses on use nanofat facial rejuvenation its potential for lipomodelling. Fat tissue “stem cell depot” contains many can differentiate various types. The Lipogem technology, developed 2013, enables isolation an intact perivascular structure, utilizing concentration mesenchymal stromal near pericytes adipose vascular system. Nowadays used primarily cosmetic purposes particularly rejuvenating improving appearance skin, especially face. Indeed, it wide applicability; be to treat fine lines, wrinkles, acne scars, sun-damaged scar repair, as alopecia treatment. However, further studies are needed assess long-term efficacy safety this technique. In conclusion, safe minimally invasive option regeneration considerable therapeutic potential. study reviews application effects medicine surgery.

Язык: Английский

---

Vaginal laser therapy for GSM/VVA: where we stand now – a review by the EUGA Working Group on Laser

Climacteric, Год журнала: 2023, Номер 26(4), С. 336 - 352

Опубликована: Июль 3, 2023

AbstractAbstractVulvovaginal atrophy (VVA) is a chronic progressive condition that involves the genital and lower urinary tracts, related to decrease of serum estrogenic levels when menopause occurs. The definition genitourinary syndrome (GSM) medically more accurate, all-encompassing publicly acceptable term than VVA. Due trend GSM, symptoms tend reappear after cessation therapy, frequently long-term treatment required. First-line therapies include vulvar vaginal lubricant or moisturizers, and, in case failure, low-dose estrogens are preferred pharmacological therapy. Populations patients, such as breast cancer (BC) survivors, affected by iatrogenic GSM with concerns about use hormonal therapies. non-ablative erbium:YAG laser fractional microablative CO2 two main lasers evaluated for treatment. aim this comprehensive review report efficacy safety Er:YAG Vaginal therapy has been demonstrated be effective restoring health, improving VVA sexual function. data suggest both safe energy-based therapeutic options management and/or postmenopausal women BC survivors.摘要外阴阴道萎缩(VVA)是一种累及生殖器和下尿路的慢性进行性疾病, 与绝经后血清雌激素水平下降有关。绝经期泌尿生殖系统综合症 的定义在医学上比VVA更准确、更全面、更容易被公众接受。由于GSM呈慢性进展趋势, 停止治疗后症状往往会再次出现, 常常需要长期治疗。一线治疗包括外阴和阴道润滑剂或保湿剂, 如果治疗失败, 首选药物治疗为低剂量阴道雌激素。乳腺癌(BC)幸存者等患者群体受到医源性GSM症状的影响, 并对激素治疗的应用感到担忧。用于GSM治疗评估的两种主要激光是非烧蚀铒和CO2阴道激光。本篇综述的目的是报告Er:YAG 和 CO2阴道激光用于GSM治疗的有效性和安全性。阴道激光治疗已被证明可以有效恢复阴道健康、改善 症状和性功能。数据表明, 安全能量的Er:YAG CO2阴道激光都是用于治疗绝经后女性和BC幸存者的VVA和/或 GSM症状的选择。Keywords: Genitourinary menopausemenopausevaginal laserCO2 lasererbium:YAG laservulvovaginal atrophybreast cancersexual function AcknowledgementsThis written on behalf European Urogynaecological Association (EUGA) Working Group.Potential conflict interestS. Athanasiou S. Salvatore declare speaker fee from being Advisory Board DEKA. L. Cardozo declares remaining authors no potential interest.Source fundingNil.

Язык: Английский

---

The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state‐of‐the‐art review

Acta Obstetricia Et Gynecologica Scandinavica, Год журнала: 2022, Номер 101(6), С. 657 - 692

Опубликована: Апрель 28, 2022

In recent years, LASER has been introduced as a minimally invasive treatment for broad range of vaginal and vulvar symptoms diseases. However, the efficacy safety continuously questioned. The aim this study is to create an overview current literature discuss controversies within use genitourinary syndrome menopause, vulvovaginal atrophy, urinary incontinence lichen sclerosus. A search string was built in PubMed. commenced on August 25, 2021 closed October 27, 2021. Two authors screened studies Covidence inclusion according eligibility criteria protocol. data were extracted from are reported both text tables. This review included 114 papers, which 15 randomized controlled trials (RCTs). effect investigated menopause 36 (six RCTs), atrophy 34 (four RCTs) 30 (two RCTs). Ten (three Half RCTs, irrespective indication, did not find significant difference improvement women treated with CO2 or Er:YAG compared their respective controls. most non-comparative after exposure across all indications. Included generally had short follow-up period only single RCT followed participants more than 6 months post treatment. Adverse events mild transient 99 including 51 094 patients provided information no serious adverse events. conclusion, found that decreases higher quality where potential biases have eliminated. We therefore stress who should be carefully monitored those indications kept research level until further high-quality evidence available.

Язык: Английский

---

Vaginal laser therapy for genitourinary syndrome of menopause – systematic review

Maturitas, Год журнала: 2021, Номер 156, С. 37 - 59

Опубликована: Июнь 20, 2021

Язык: Английский

---

Emerging Use of Vaginal Laser to Treat Genitourinary Syndrome of Menopause for Breast Cancer Survivors: A Review

Medicina, Год журнала: 2023, Номер 59(1), С. 132 - 132

Опубликована: Янв. 9, 2023

Breast cancer treatment, such as chemotherapy and endocrine therapy, can cause earlier more sudden menopausal symptoms. Genitourinary syndrome of menopause (GSM) is one the most bothersome side effects breast resulting in sexual dysfunction impaired quality life. GSM includes genital, urinary, However, alleviating symptoms for survivors may be challenging due to ineffectiveness, contraindications, low adherence treatment. The recent data show feasibility safety vaginal laser treat survivors. This narrative review provides aspects patients, putting focus on efficacy therapy.

Язык: Английский

---

Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Current Perspectives on the Role of Laser Therapy

International Journal of Women s Health, Год журнала: 2023, Номер Volume 15, С. 1261 - 1282

Опубликована: Авг. 1, 2023

Abstract: Genitourinary syndrome of menopause (GSM) is a frequent consequence iatrogenic or anti-estrogenic adjuvant therapies in breast cancer survivors (BCSs). GSM may profoundly affect sexual health and quality life, multidimensional unique model care needed to address the burden this chronic heterogeneous condition. Severe symptoms be insufficiently managed with non-hormonal traditional treatments, such as moisturizers lubricants, recommended first-line approach by current guidelines, because concerns exist around use vaginal estrogens, particularly women on aromatase inhibitors (AIs). Vaginal laser therapy has emerged promising alternative who are not suitable do respond hormonal management, willing pharmacological strategies. We aim systematically review evidence about efficacy safety BCSs highlight gaps literature. analyzed results from 20 studies, including over 700 treated either CO 2 erbium laser, quite primary outcomes duration follow up (4 weeks– 24 months). Although for comes mostly single-arm prospective only one randomized double-blind sham-controlled trial comparative hyaluronic acid, available data reassuring short term indicate effectiveness both lasers most common symptoms. However, further studies mandatory establish long-term menopausal women, BCSs. Keywords: genitourinary menopause, GSM, cancer, vulvovaginal atrophy, VVA

Язык: Английский

---

The Role of Physical Exercise in Sexual Health and Body Image in Women Living with and Surviving Breast Cancer: A Scoping Review

Healthcare, Год журнала: 2025, Номер 13(7), С. 741 - 741

Опубликована: Март 26, 2025

Background/Objective. Breast Cancer (BC) is a growing medical concern that may heavily influence sexual functioning (SF) and body image (BI) in BC patients. In healthy individuals, physical exercise (PE) has been proposed as crucial factor to improve BI. However, little known about the effects of PE on BI SF Therefore, aim this study summarize extant literature regarding these populations. Methods. Our review, conducted using PRISMA extension for Scoping Review, was carried out three databases: PubMed, Scopus Web Science. Only Randomized Control Trials (RCT) evaluating different types and/or population affected by or who have survived were included. Results. The search yielded 488 studies. Twelve studies resulted being eligible inclusion review. aerobic scant. Studies employing resistance training provided contrasting results. Conversely, holistic approaches larger benefits SF. Conclusions. results showed marginal interventions longer than six months based activities should be implemented To safely draw conclusions SF, future consider more accurate monitoring intensity, thorough evaluation possible mediators

Язык: Английский

---

CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial

Cancers, Год журнала: 2025, Номер 17(7), С. 1241 - 1241

Опубликована: Апрель 6, 2025

We aimed to study the efficacy of fractional CO2 laser for genitourinary syndrome menopause (GSM) symptoms in breast cancer (BC) survivors through a randomized, sham-controlled study, followed by an open-phase assessing impact additional treatments. BC with GSM were randomized receive either three sessions intravaginal or sham treatment every 3-4 weeks. The laser's energy was 45-60 mJ/pixel. Outcomes compared one month following last session. Participants initially receiving offered more sessions, while those had six open-label study. Thirty-four (n = 19) 15) Dyspareunia and intercourse dryness scores improved both groups post-treatment, without significant advantage over sham. resulted reduction daily (-1.30 ± 0.55, p 0.017), increase vaginal hydration (3.24 1.13, 0.004), Vaginal Health Index (VHI) (2.26 0.50, < 0.001). Most participants (18/19 9/15, respectively) opted continue treatments after unblinding, resulting 27 patients Increasing number associated constant improvement Visual Analogue Score (VAS) dyspareunia, dryness, burning, discomfort, itch, average VAS, as well pH, VHI, hydration. Conclusions Three reduced but did not improve dyspareunia sexual when this trial. seemed outcomes; however, it remained clinically insufficient, even

Язык: Английский

---